1,248 search results for “drug delivery” in the Public website
-
Mathematical modelling of adverse outcome pathways
In this project, we aim to develop mathematical models to mechanistically and quantitatively predict the dynamics of cellular stress pathway activation and its relation with toxic effects when cells are exposed to various toxicants.
-
In vivo modelling of Ewing sarcoma in zebrafish
Promotores: Prof.dr. P.C.W. Hogendoorn & Prof.dr. H.P. Spaink, Co-promotor: Dr. B.E. Snaar-Jagalska
-
Illuminating N-acylethanolamine biosynthesis with new chemical tools
In this thesis, the discovery and optimization is described of chemical tools to study the N-acylethanolamine (NAE) biosynthetic pathway.
-
Cancer chess: molecular insights into PARP inhibitor resistance
The clinical potential of applying synthetic lethality to cancer treatment is famously demonstrated by the BRCA1/PARP1 paradigm: a tumor specific defect in BRCA1 – a component of the DNA double-strand break (DSB) repair pathway homologous recombination (HR) – results in a remarkable sensitivity to PARP1…
-
Biological evaluations of nanocarriers to improve the effectiveness of colorectal cancer treatment
PhD defence
-
More effective blocking of CCR2 receptor
The discovery of new medicines is a tedious and lengthy process. On average, over 10,000 molecules need to be studied for one to become a drug and reach the patient. Part of that process are the very costly clinical trials in humans, and candidate drugs often fail due to side effects or lack of efficacy.…
-
Novel Chemical Modalities
The Novel chemical modalities research group is headed by Assistant Professor Sebastian Pomplun. Sebastian started at the division of Medicinal Chemistry within the LACDR in September 2021. His lab develops technologies for the discovery of novel chemical modalities that can address challenging drug…
-
Laura Heitman appointed as Professor of Molecular Pharmacology
As of 1 November, Laura Heitman has been appointed full Professor of Molecular Pharmacology at the Leiden Academic Centre for Drug Research (LACDR). Heitman has been working on the understanding and improvement of drug-receptor interactions in early drug discovery. ‘My ultimate aim is to make medicines…
-
Research
The current projects of the Molecular Physiology group focus on proteins of the endocannabinoid system, kinases and antibacterial targets. MSc- and BSc-students can contact Jessica van Krimpen-Kraaijenoord to apply for research internships.
-
A much-needed new class of antibiotics
Antimicrobial resistance (AMR) is the phenomenon that pathogens become insensitive to the antibiotics that we use against them. A growing number of pathogens is becoming resistant, with methicillin-resistant S. aureus (MRSA) as the most famous example. But while the threat of AMR represents a slow-moving…
-
Concepts and applications for evidence-based dosing in morbidly obese patients before and after weight loss surgery
Promotor: C.A.J. Knibbe, Co-promotores: H.P.A. van Dongen, B. van Ramshorst
-
Single cell technologies for mechanobiology and mechanopharmacology
Mechanobiology is a major area in biology, however, mechanics is currently a missing element in drug development pipelines. This has led to a high cost for the society. Mechanotoxicity of drugs often appears as a long-term side effect of drugs, and has led to removal of drugs from the market. Furthermore,…
-
Systems pharmacology of human neuroendocrine disease entities
An important hormone excreting gland in the human body is the pituitary
-
Prediction of brain target site concentrations on the basis of CSF PK: impact of mechanisms of blood-to-brain transport and within brain distribution
Promotor: Prof.dr. M. Danhof, Co-promotor: E.C.M. de Lange
-
New resource for the modelling community
The Repository from the Drug Disease Model Resources (DDMoRe) consortium provides a home to a collection of computational models of disease and drug action that have been used in pharmaceutical and/or academic research. This publically available open-access resource will make it easier for researchers…
-
Oncode Accelerator
Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process. Leiden University, the LUMC and other partners will implement this new way…
-
Hit Discovery
The goal of hit discovery is to identify suitable chemical starting points to modulate a drug target. A hit can be, a.o., a small molecule, a protein or mRNA. Hit identification is performed via rational design, genome mining, (targeted) library screening, or in silico approaches.
-
Contact
Division contact information & address
-
New techniques for tuberculosis treatment
About nine million people worldwide contract tuberculosis each year. Research into new treatment for this disease has received fresh stimulus with more efficient techniques and a new understanding of how the tuberculosis bacteria works.
-
Systems Biomedicine and Pharmacology (MSc)
The two-years master’s specialisation System Biomedicine and Pharmacology at Leiden university focuses on predicting drug response with computational modelling, developing individualised therapies, and developing innovative analytical tools for personalised health strategies.
-
The activation mechanisms of G protein-coupled receptors: the case of the adenosine A2B and HCA2/3 receptors
Promotor: A.P. IJzerman
-
Dosing considerations for preterm neonates: from pharmacometrics to clinical practice
Prematurely born neonates require, amongst others, pharmaceutical therapy. Dosing guidelines for these therapies are often based on data from term born neonates or older infants, while these are not necessarily similar to prematurely born neonates.
-
Allosteric modulation and ligand binding kinetics at the Kv11.1 channel
Promotor: Prof.dr. A.P. IJzerman, Co-Promotor: L.H. Heitman
-
Laura Heitman nominated for Prix Galien
Laura Heitman of the Leiden Academic Center for Drug Research (LACDR) has been nominated for the Prix Galien Research Award. This important pharmaceutical prize honors young, prominent researchers whose scientific research is of great importance for fundamental or clinical drug research.
- Research
-
Quantitative Clinical Pharmacology
The Quantitative Clinical Pharmacology group is led by Prof. Dr. Catherijne Knibbe. Her research group aims to define how to adjust a drug dose in special patient populations such as (prematurely born) neonates or children, obese individuals or critically ill patients. Through combining the statistical…
-
Precision modeling of breast cancer in the CRISPR era
The molecular mechanisms that instigate a healthy cell to become malignant are fueled by (epi)genetic alterations in so-called driver genes.
-
NMR studies of protein-small molecule and protein-peptide interactions
Promotor: M. Ubbink, Co-promotor: G. Siegal
-
25 Years Bio-Pharmaceutical Sciences: Combined fascination
25 Years ago, the Center for Bio-Pharmaceutical Sciences was founded at Leiden University; one year later, in 1985, the education program of Bio-Pharmaceutical Sciences started. On Friday September 18th, this was celebrated with a Symposium, an anniversary booklet, and a grand party.
-
Research
Tuberculosis causes 1.5 million deaths yearly and anti-tuberculosis therapies are threatened by emergence of drug resistance. Development of innovative drug combinations should be accelerated with the use of translational pharmacological models. Moreover, host-directed therapies (HDT), which stimulate…
-
Education
Our educational programmes span the entire spectrum of pharmaceutical education, from training of the next generation drug researchers in the areas of drug design, drug action, and drug use to educating the pharmacists of the future.
-
History
Life Sciences Artificial Intelligence Data Science
-
Using Value-Based Health Care Principles To "Fix" Orthopaedic Care Delivery
PhD defence
-
Bio-Pharmaceutical Sciences (BSc)
As a student of Bio-Pharmaceutical Sciences, you have a strong interest in drug development: from the onset of diseases to the effects of individual drugs in the body. Is that true for you? Then, Bio-Pharmaceutical Sciences might be the right study programme for you!
-
Determining the kinetic profile of ENT1 inhibitors
Supervisor: Anna Vlachodimou
-
Flagships
In CCLS several subgroups have formed, below you can find an overview of these groups with the names of the leading researchers and a short outline of the project.
-
Cannabinoid receptor 2 as a ‘drugable’ target: kinetic profile of novel receptor ligands
Supervisor: Andrea Martella
-
Programme structure
The Drug Discovery and Safety specialisation consists of compulsory and optional components.
-
LED3 Lecture: Molecular glues in drug discovery
Lecture
-
Steffen Brünle
Science
s.bruenle@lic.leidenuniv.nl | +31 71 527 4544
-
Two-pronged attack on infectious diseases
A combination of two potential drugs gives hope of a 'super blockage' of an over-active immune system, Leiden researchers report in Nature. The breakthrough came from the crystallisation of a membrane protein.
-
Cancer cells: A closer look
What distinguishes a tumour cell from a healthy cell? Researchers are trying to answer this question as precisely as possible. Certain differences could eventually lead to new therapies.
-
Cancer research focusing on quality of life
Cancer is one of the main causes of death in the Netherlands. Leiden researchers are working to improve the treatment of different types of cancer in order to increase the patient’s quality of life. A better understanding of how cancer develops will make it possible to deliver personalised and precise…
-
NWO grant for smart software that searches for new medicines
Gerard van Westen and his group, together with pharmaceutical company Galapagos, start on developing software that invents new effective molecules. They will receive an NWO LIFT grant of 280,000 euros, of which 63,000 euros will come from Galapagos. The company will also bring its expertise in biology,…
-
Key publications
Key publications of the Antiviral Pharmacology group.
-
Prediction of human gut (colon cancer) target site concentrations and PKPD relationships
The advanced insights obtained for the CNS PBPK model development are currently used to develop advanced mathematical models for drug distribution prediction in other body tissues protected by barriers, such as the gut. The gut PBPK model will be linked to drug effects for treatment of colon cancer.
-
Personalized drug repositioning using gene expression
PhD defence
-
Quantitative pharmacology of antimicrobials
Antimicrobial drugs constitute a fundamental part of modern medicine. The global rise in antimicrobial resistance poses a major threat to global health.
-
NACTAR: The lugdunomycins: a new class of polyketide antibiotics with unique chemical scaffold
Aim of the proposal is to develop lugdunomycin into a drug candidate able to treat infectious diseases caused by multi-drug resistant pathogens.
-
Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474, SCIENCE, 2017
The drug BIA 10-2474 inhibits fatty acid amide hydrolase (FAAH), a lipase that degrades a specific endocannabinoid. On the basis of this activity, BIA 10-2474 was being developed as a potential treatment for anxiety and pain. In a phase 1 trial of the drug, one subject died, and four others suffered…